Loading…
TIM-3 as a novel therapeutic target for eradicating acute myelogenous leukemia stem cells
Acute myelogenous leukemia (AML) originates from self-renewing leukemic stem cells (LSCs), which represent the ultimate therapeutic target for AML. Recent studies have identified several AML LSC-specific surface antigens as candidate targets of therapeutic molecules. T cell immunoglobulin mucin-3 (T...
Saved in:
| Published in: | International journal of hematology 2013-12, Vol.98 (6), p.627-633 |
|---|---|
| Main Authors: | , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c505t-7ceac449907fe75bf9b45ac454b65298907cb31a809fe1ba7d59f6dd26dec4163 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c505t-7ceac449907fe75bf9b45ac454b65298907cb31a809fe1ba7d59f6dd26dec4163 |
| container_end_page | 633 |
| container_issue | 6 |
| container_start_page | 627 |
| container_title | International journal of hematology |
| container_volume | 98 |
| creator | Kikushige, Yoshikane Miyamoto, Toshihiro |
| description | Acute myelogenous leukemia (AML) originates from self-renewing leukemic stem cells (LSCs), which represent the ultimate therapeutic target for AML. Recent studies have identified several AML LSC-specific surface antigens as candidate targets of therapeutic molecules. T cell immunoglobulin mucin-3 (TIM-3) is expressed on LSCs in most types of AML, with the exception of acute promyelocytic leukemia, but not on normal hematopoietic stem cells (HSCs). In xenograft models reconstituted with human AML LSCs or HSCs, an anti-human TIM-3 mouse IgG2a antibody with cytotoxic activities eradicates AML LSCs in vivo, but does not affect normal human hematopoiesis. Thus, TIM-3 is a promising therapeutic target for the eradication of AML LSCs. |
| doi_str_mv | 10.1007/s12185-013-1433-6 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1466374847</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3148139211</sourcerecordid><originalsourceid>FETCH-LOGICAL-c505t-7ceac449907fe75bf9b45ac454b65298907cb31a809fe1ba7d59f6dd26dec4163</originalsourceid><addsrcrecordid>eNp1kEtLxDAYRYMoOj5-gBsJuHETTZpXuxTxMaC4GReuQpp-Hat9jEkq-O9NmVFEcBW4Obm5HISOGT1nlOqLwDKWS0IZJ0xwTtQWmrFcScK1FttoRotMEqkZ3UP7IbxSyjQVehftZYIKxXQ-Q8-L-QPh2AZscT98QIvjC3i7gjE2DkfrlxBxPXicwqpxNjb9Els3RsDdJ7TDEvphDLiF8Q26xuIQocMO2jYcop3atgGONucBerq5XlzdkfvH2_nV5T1xkspItAPrhCgKqmvQsqyLUsiUSFEqmRV5yl3Jmc1pUQMrra5kUauqylQFTjDFD9DZunflh_cRQjRdE6YFtoc0zTChFNciFzqhp3_Q12H0fVo3UVIUVGqeKLamnB9C8FCblW866z8No2bybtbeTfJuJu9mGnGyaR7LDqqfF9-iE5CtgZCu-iX4X1__2_oFKeqNAA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1465490573</pqid></control><display><type>article</type><title>TIM-3 as a novel therapeutic target for eradicating acute myelogenous leukemia stem cells</title><source>Springer Nature</source><creator>Kikushige, Yoshikane ; Miyamoto, Toshihiro</creator><creatorcontrib>Kikushige, Yoshikane ; Miyamoto, Toshihiro</creatorcontrib><description>Acute myelogenous leukemia (AML) originates from self-renewing leukemic stem cells (LSCs), which represent the ultimate therapeutic target for AML. Recent studies have identified several AML LSC-specific surface antigens as candidate targets of therapeutic molecules. T cell immunoglobulin mucin-3 (TIM-3) is expressed on LSCs in most types of AML, with the exception of acute promyelocytic leukemia, but not on normal hematopoietic stem cells (HSCs). In xenograft models reconstituted with human AML LSCs or HSCs, an anti-human TIM-3 mouse IgG2a antibody with cytotoxic activities eradicates AML LSCs in vivo, but does not affect normal human hematopoiesis. Thus, TIM-3 is a promising therapeutic target for the eradication of AML LSCs.</description><identifier>ISSN: 0925-5710</identifier><identifier>EISSN: 1865-3774</identifier><identifier>DOI: 10.1007/s12185-013-1433-6</identifier><identifier>PMID: 24046178</identifier><language>eng</language><publisher>Tokyo: Springer Japan</publisher><subject>Animals ; Antibodies, Monoclonal - pharmacology ; Antibodies, Monoclonal - therapeutic use ; Antineoplastic Agents - pharmacology ; Antineoplastic Agents - therapeutic use ; Hematology ; Hematopoiesis - genetics ; Hepatitis A Virus Cellular Receptor 2 ; Humans ; Leukemia, Myeloid, Acute - drug therapy ; Leukemia, Myeloid, Acute - metabolism ; Medicine ; Medicine & Public Health ; Membrane Proteins - antagonists & inhibitors ; Membrane Proteins - genetics ; Membrane Proteins - metabolism ; Mice ; Molecular Targeted Therapy ; Neoplastic Stem Cells - drug effects ; Neoplastic Stem Cells - metabolism ; Oncology ; Progress in Hematology</subject><ispartof>International journal of hematology, 2013-12, Vol.98 (6), p.627-633</ispartof><rights>The Japanese Society of Hematology 2013</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c505t-7ceac449907fe75bf9b45ac454b65298907cb31a809fe1ba7d59f6dd26dec4163</citedby><cites>FETCH-LOGICAL-c505t-7ceac449907fe75bf9b45ac454b65298907cb31a809fe1ba7d59f6dd26dec4163</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24046178$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kikushige, Yoshikane</creatorcontrib><creatorcontrib>Miyamoto, Toshihiro</creatorcontrib><title>TIM-3 as a novel therapeutic target for eradicating acute myelogenous leukemia stem cells</title><title>International journal of hematology</title><addtitle>Int J Hematol</addtitle><addtitle>Int J Hematol</addtitle><description>Acute myelogenous leukemia (AML) originates from self-renewing leukemic stem cells (LSCs), which represent the ultimate therapeutic target for AML. Recent studies have identified several AML LSC-specific surface antigens as candidate targets of therapeutic molecules. T cell immunoglobulin mucin-3 (TIM-3) is expressed on LSCs in most types of AML, with the exception of acute promyelocytic leukemia, but not on normal hematopoietic stem cells (HSCs). In xenograft models reconstituted with human AML LSCs or HSCs, an anti-human TIM-3 mouse IgG2a antibody with cytotoxic activities eradicates AML LSCs in vivo, but does not affect normal human hematopoiesis. Thus, TIM-3 is a promising therapeutic target for the eradication of AML LSCs.</description><subject>Animals</subject><subject>Antibodies, Monoclonal - pharmacology</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Hematology</subject><subject>Hematopoiesis - genetics</subject><subject>Hepatitis A Virus Cellular Receptor 2</subject><subject>Humans</subject><subject>Leukemia, Myeloid, Acute - drug therapy</subject><subject>Leukemia, Myeloid, Acute - metabolism</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Membrane Proteins - antagonists & inhibitors</subject><subject>Membrane Proteins - genetics</subject><subject>Membrane Proteins - metabolism</subject><subject>Mice</subject><subject>Molecular Targeted Therapy</subject><subject>Neoplastic Stem Cells - drug effects</subject><subject>Neoplastic Stem Cells - metabolism</subject><subject>Oncology</subject><subject>Progress in Hematology</subject><issn>0925-5710</issn><issn>1865-3774</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><recordid>eNp1kEtLxDAYRYMoOj5-gBsJuHETTZpXuxTxMaC4GReuQpp-Hat9jEkq-O9NmVFEcBW4Obm5HISOGT1nlOqLwDKWS0IZJ0xwTtQWmrFcScK1FttoRotMEqkZ3UP7IbxSyjQVehftZYIKxXQ-Q8-L-QPh2AZscT98QIvjC3i7gjE2DkfrlxBxPXicwqpxNjb9Els3RsDdJ7TDEvphDLiF8Q26xuIQocMO2jYcop3atgGONucBerq5XlzdkfvH2_nV5T1xkspItAPrhCgKqmvQsqyLUsiUSFEqmRV5yl3Jmc1pUQMrra5kUauqylQFTjDFD9DZunflh_cRQjRdE6YFtoc0zTChFNciFzqhp3_Q12H0fVo3UVIUVGqeKLamnB9C8FCblW866z8No2bybtbeTfJuJu9mGnGyaR7LDqqfF9-iE5CtgZCu-iX4X1__2_oFKeqNAA</recordid><startdate>20131201</startdate><enddate>20131201</enddate><creator>Kikushige, Yoshikane</creator><creator>Miyamoto, Toshihiro</creator><general>Springer Japan</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7T5</scope><scope>7T7</scope><scope>7TM</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20131201</creationdate><title>TIM-3 as a novel therapeutic target for eradicating acute myelogenous leukemia stem cells</title><author>Kikushige, Yoshikane ; Miyamoto, Toshihiro</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c505t-7ceac449907fe75bf9b45ac454b65298907cb31a809fe1ba7d59f6dd26dec4163</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Animals</topic><topic>Antibodies, Monoclonal - pharmacology</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Hematology</topic><topic>Hematopoiesis - genetics</topic><topic>Hepatitis A Virus Cellular Receptor 2</topic><topic>Humans</topic><topic>Leukemia, Myeloid, Acute - drug therapy</topic><topic>Leukemia, Myeloid, Acute - metabolism</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Membrane Proteins - antagonists & inhibitors</topic><topic>Membrane Proteins - genetics</topic><topic>Membrane Proteins - metabolism</topic><topic>Mice</topic><topic>Molecular Targeted Therapy</topic><topic>Neoplastic Stem Cells - drug effects</topic><topic>Neoplastic Stem Cells - metabolism</topic><topic>Oncology</topic><topic>Progress in Hematology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kikushige, Yoshikane</creatorcontrib><creatorcontrib>Miyamoto, Toshihiro</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Proquest Nursing & Allied Health Source</collection><collection>Immunology Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Nucleic Acids Abstracts</collection><collection>ProQuest Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kikushige, Yoshikane</au><au>Miyamoto, Toshihiro</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>TIM-3 as a novel therapeutic target for eradicating acute myelogenous leukemia stem cells</atitle><jtitle>International journal of hematology</jtitle><stitle>Int J Hematol</stitle><addtitle>Int J Hematol</addtitle><date>2013-12-01</date><risdate>2013</risdate><volume>98</volume><issue>6</issue><spage>627</spage><epage>633</epage><pages>627-633</pages><issn>0925-5710</issn><eissn>1865-3774</eissn><abstract>Acute myelogenous leukemia (AML) originates from self-renewing leukemic stem cells (LSCs), which represent the ultimate therapeutic target for AML. Recent studies have identified several AML LSC-specific surface antigens as candidate targets of therapeutic molecules. T cell immunoglobulin mucin-3 (TIM-3) is expressed on LSCs in most types of AML, with the exception of acute promyelocytic leukemia, but not on normal hematopoietic stem cells (HSCs). In xenograft models reconstituted with human AML LSCs or HSCs, an anti-human TIM-3 mouse IgG2a antibody with cytotoxic activities eradicates AML LSCs in vivo, but does not affect normal human hematopoiesis. Thus, TIM-3 is a promising therapeutic target for the eradication of AML LSCs.</abstract><cop>Tokyo</cop><pub>Springer Japan</pub><pmid>24046178</pmid><doi>10.1007/s12185-013-1433-6</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0925-5710 |
| ispartof | International journal of hematology, 2013-12, Vol.98 (6), p.627-633 |
| issn | 0925-5710 1865-3774 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1466374847 |
| source | Springer Nature |
| subjects | Animals Antibodies, Monoclonal - pharmacology Antibodies, Monoclonal - therapeutic use Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use Hematology Hematopoiesis - genetics Hepatitis A Virus Cellular Receptor 2 Humans Leukemia, Myeloid, Acute - drug therapy Leukemia, Myeloid, Acute - metabolism Medicine Medicine & Public Health Membrane Proteins - antagonists & inhibitors Membrane Proteins - genetics Membrane Proteins - metabolism Mice Molecular Targeted Therapy Neoplastic Stem Cells - drug effects Neoplastic Stem Cells - metabolism Oncology Progress in Hematology |
| title | TIM-3 as a novel therapeutic target for eradicating acute myelogenous leukemia stem cells |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T13%3A57%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=TIM-3%20as%20a%20novel%20therapeutic%20target%20for%20eradicating%20acute%20myelogenous%20leukemia%20stem%20cells&rft.jtitle=International%20journal%20of%20hematology&rft.au=Kikushige,%20Yoshikane&rft.date=2013-12-01&rft.volume=98&rft.issue=6&rft.spage=627&rft.epage=633&rft.pages=627-633&rft.issn=0925-5710&rft.eissn=1865-3774&rft_id=info:doi/10.1007/s12185-013-1433-6&rft_dat=%3Cproquest_cross%3E3148139211%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c505t-7ceac449907fe75bf9b45ac454b65298907cb31a809fe1ba7d59f6dd26dec4163%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1465490573&rft_id=info:pmid/24046178&rfr_iscdi=true |